ProCE Banner Activity

Phase Ib/II Trial of APR-246 + Azacitidine in TP53-Mutant MDS and AML

Slideset Download
Conference Coverage
In patients with TP53-mutant MDS/AML, APR-246 plus azacitidine was active and generally well tolerated.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company